Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
Beyond Truvada – what is the future of PrEP?

Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate/emtricitabine (Truvada) has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in

Published
31 October 2018
By
Roger Pebody
Boston HIV clinic sees 90% reduction in infections in people being prescribed PrEP

The Fenway clinic in Boston, Massachusetts, one of the first to institute a large pre-exposure prophylaxis (PrEP) programme in the USA, has seen a reduction

Published
30 October 2018
By
Gus Cairns
First large HIV prevention trial using antibodies will probably not be the last

The HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week was dominated by studies of one type of molecule – broadly neutralising antibodies

Published
29 October 2018
By
Gus Cairns
Generic PrEP bought online has correct amounts of emtricitabine and tenofovir

People buying generic PrEP (pre-exposure prophylaxis) online can be confident they are buying the real thing, according to research presented to the International Congress on Drug Therapy

Published
28 October 2018
By
Michael Carter
The long tail of injectable PrEP is especially long for women

Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around

Published
25 October 2018
By
Roger Pebody
How substance use affects adherence to PrEP among gay and bisexual men

On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

Published
24 October 2018
From
Medical Xpress
Another rare PrEP failure reported in San Francisco

A San Francisco man was apparently infected with partially resistant HIV despite consistent use of Truvada pre-exposure prophylaxis (PrEP), according to a poster presented at IDWeek 2018, held

Published
09 October 2018
By
Liz Highleyman
First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

A poster presentation at IDWeek, a yearly conference held by the Infectious Diseases Society of America, revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). This new report is unique for several reasons, primarily because this is the first known HIV seroconversion with verified adherence to PrEP in the U.S.

Published
07 October 2018
From
The Body Pro
Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

Published
01 October 2018
From
The Body Pro
Swapping daily pills for monthly shots could transform HIV treatment and prevention

New results are raising hopes for easing one challenge of living with HIV: the need to take daily pills for life, both to ward off AIDS and to lower the risk of transmitting the virus to others. Missing doses can also foster the emergence of HIV strains with drug resistance, a danger both to the person receiving treatment and, if those strains spread, to entire populations. Now, a large-scale study has shown over 48 weeks that monthly injections of two long-acting anti-HIV drugs work just as well as taking daily pills.

Published
23 August 2018
From
Science

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.